Short report: Autistic gastrointestinal and eating symptoms treated with secretin: A subtype of autism

Stefano Pallanti; Stefano Lassi; Giampaolo La Malfa; Marco Campigli; Roberto Di Rubbo; Giulia Paolini; Valentina Cesarali

doi:10.1186/1745-0179-1-24

Short report: Autistic gastrointestinal and eating symptoms treated with secretin: A subtype of autism

Stefano Pallanti, Stefano Lassi, Giampaolo La Malfa, Marco Campigli, Roberto Di Rubbo, Giulia Paolini, Valentina Cesarali

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Pervasive Developmental Disorders (PDD) are chronic, lifelong disorders for which there is as yet no effective cure, and medical management remains a challenge for clinicians. The current report describes two patients affected by autistic disorder with associated gastrointestinal symptoms. They received multiple doses of intravenous secretin for a six-month period and were assessed with several specific outcome measures to evaluate drug effect. The administration of secretin led to some significant and lasting improvement in only one case. Gastroesophageal reflux may contribute to some of the behavioural problems and explain the effect of secretin since its suppressive effect on gastric secretion is well known. It is also true that autistic children with gastroesophageal reflux and a higher IQ could constitute a subtype which responds to secretin administration and that could be labelled as a "gastrointestinal subtype"

Original language	English
Article number	24
Journal	Clinical Practice and Epidemiology in Mental Health
Volume	1
DOIs	https://doi.org/10.1186/1745-0179-1-24
State	Published - 15 Nov 2005
Externally published	Yes

Access to Document

10.1186/1745-0179-1-24

Cite this

@article{68823f20e59a4d0cbc67cae8b45710d0,

title = "Short report: Autistic gastrointestinal and eating symptoms treated with secretin: A subtype of autism",

abstract = "Pervasive Developmental Disorders (PDD) are chronic, lifelong disorders for which there is as yet no effective cure, and medical management remains a challenge for clinicians. The current report describes two patients affected by autistic disorder with associated gastrointestinal symptoms. They received multiple doses of intravenous secretin for a six-month period and were assessed with several specific outcome measures to evaluate drug effect. The administration of secretin led to some significant and lasting improvement in only one case. Gastroesophageal reflux may contribute to some of the behavioural problems and explain the effect of secretin since its suppressive effect on gastric secretion is well known. It is also true that autistic children with gastroesophageal reflux and a higher IQ could constitute a subtype which responds to secretin administration and that could be labelled as a {"}gastrointestinal subtype{"}",

author = "Stefano Pallanti and Stefano Lassi and {La Malfa}, Giampaolo and Marco Campigli and {Di Rubbo}, Roberto and Giulia Paolini and Valentina Cesarali",

year = "2005",

month = nov,

day = "15",

doi = "10.1186/1745-0179-1-24",

language = "English",

volume = "1",

journal = "Clinical Practice and Epidemiology in Mental Health",

issn = "1745-0179",

publisher = "Bentham Science Publishers",

}

TY - JOUR

T1 - Short report

T2 - Autistic gastrointestinal and eating symptoms treated with secretin: A subtype of autism

AU - Pallanti, Stefano

AU - Lassi, Stefano

AU - La Malfa, Giampaolo

AU - Campigli, Marco

AU - Di Rubbo, Roberto

AU - Paolini, Giulia

AU - Cesarali, Valentina

PY - 2005/11/15

Y1 - 2005/11/15

N2 - Pervasive Developmental Disorders (PDD) are chronic, lifelong disorders for which there is as yet no effective cure, and medical management remains a challenge for clinicians. The current report describes two patients affected by autistic disorder with associated gastrointestinal symptoms. They received multiple doses of intravenous secretin for a six-month period and were assessed with several specific outcome measures to evaluate drug effect. The administration of secretin led to some significant and lasting improvement in only one case. Gastroesophageal reflux may contribute to some of the behavioural problems and explain the effect of secretin since its suppressive effect on gastric secretion is well known. It is also true that autistic children with gastroesophageal reflux and a higher IQ could constitute a subtype which responds to secretin administration and that could be labelled as a "gastrointestinal subtype"

AB - Pervasive Developmental Disorders (PDD) are chronic, lifelong disorders for which there is as yet no effective cure, and medical management remains a challenge for clinicians. The current report describes two patients affected by autistic disorder with associated gastrointestinal symptoms. They received multiple doses of intravenous secretin for a six-month period and were assessed with several specific outcome measures to evaluate drug effect. The administration of secretin led to some significant and lasting improvement in only one case. Gastroesophageal reflux may contribute to some of the behavioural problems and explain the effect of secretin since its suppressive effect on gastric secretion is well known. It is also true that autistic children with gastroesophageal reflux and a higher IQ could constitute a subtype which responds to secretin administration and that could be labelled as a "gastrointestinal subtype"

UR - http://www.scopus.com/inward/record.url?scp=33845227177&partnerID=8YFLogxK

U2 - 10.1186/1745-0179-1-24

DO - 10.1186/1745-0179-1-24

M3 - Article

AN - SCOPUS:33845227177

SN - 1745-0179

VL - 1

JO - Clinical Practice and Epidemiology in Mental Health

JF - Clinical Practice and Epidemiology in Mental Health

M1 - 24

ER -

Short report: Autistic gastrointestinal and eating symptoms treated with secretin: A subtype of autism

Abstract

Access to Document

Fingerprint

Cite this